1. Home
  2. JRS vs HURA Comparison

JRS vs HURA Comparison

Compare JRS & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen Real Estate Income Fund of Beneficial Interest

JRS

Nuveen Real Estate Income Fund of Beneficial Interest

N/A

Current Price

$7.44

Market Cap

210.6M

Sector

Finance

ML Signal

N/A

Logo TuHURA Biosciences Inc.

HURA

TuHURA Biosciences Inc.

N/A

Current Price

$1.37

Market Cap

123.0M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
JRS
HURA
Founded
2001
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
210.6M
123.0M
IPO Year
N/A
2010

Fundamental Metrics

Financial Performance
Metric
JRS
HURA
Price
$7.44
$1.37
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
★ $8.04
AVG Volume (30 Days)
60.2K
★ 545.3K
Earning Date
01-01-0001
11-13-2026
Dividend Yield
★ 8.87%
N/A
EPS Growth
N/A
★ 47.93
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.12
$0.41
52 Week High
$8.90
$3.43

Technical Indicators

Market Signals
Indicator
JRS
HURA
Relative Strength Index (RSI) 43.55 33.39
Support Level $7.12 $1.27
Resistance Level $8.32 $2.22
Average True Range (ATR) 0.15 0.16
MACD -0.02 -0.03
Stochastic Oscillator 22.81 13.38

Price Performance

Historical Comparison
JRS
HURA

About JRS Nuveen Real Estate Income Fund of Beneficial Interest

Nuveen Real Estate Income Fund is a diversified closed-end investment company. The Fund s investment objective is to provide total return through high current income and capital appreciation.

About HURA TuHURA Biosciences Inc.

TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.

Share on Social Networks: